Long-time partners Medrio and HMD Clinical have come together, with Medrio acquiring the randomization and trial supply management (RTSM) firm for an undisclosed amount. The deal closed this month and San Francisco-based Medrio has already redirected the UK company’s webpage to its domain.
As a leader in the eClinical space, Medrio is betting on HMD Clinical’s RTSM expertise to expand its offerings to trial sponsors, sites and clinical research organizations (CROs) around the world. With the company already providing all the tools needed for complete electronic data capture (EDC) — including ePRO, eConsent and eSource — the acquisition of HMD Clinical will deliver more front-end support to trial sites through improved supply management and better study oversight.
“Our long-standing partnership with HMD Clinical and existing integrations will ensure a smooth transition for customers,” said Ed Gould, chief financial officer of Medrio, in a press release. “Both HMD and Medrio pride themselves on having developed flexible technology, and as such, system integration has gone smoothly. As we look to continue to grow our organization, HMD Clinical’s portfolio, culture, and mission-aligned with ours, and ultimately will allow us to continue to offer best-in-class service and technology solutions to our customers.”
The two companies have the benefit of having previously worked together on countless projects, meaning their respective technologies were designed to be combined. In fact, over the past 18 years, Medrio has delivered over 250,000 units to more than 2,400 sites across 50 countries.
According to Ian Davison, HMD Clinical’s co-founder and operations director, it was their shared “common vision and worldview” that encouraged them to offer HMD Clinical up to Medrio.
“We didn’t decide to sell HMD Clinical,” said Davidson. “We decided to sell HMD Clinical to Medrio. That’s an important distinction.”
Davidson and his HMD co-founder Brent Harlow, who also serves as the project director for the company, will continue their work with Medrio to further develop the integrated RTSM software.
The company’s acquisition of HMD is just the latest in what has been a busy year for Medrio. In August 2020, Nicole Latimer took over as Medrio’s CEO after the company’s founder and former CEO, Mike Novotny, announced he’d be taking a sabbatical.
“Both Ian and Brent have been instrumental in building HMD Clinical from the ground up and it’s clear that their customers and staff have tremendous trust in their expertise and ability to deliver distinguished solutions,” said Latimer. “We are thrilled they are joining the Medrio family along with all other HMD Clinical staff and know our customers will benefit from their expertise and continued innovation.”